# Relmada Therapeutics Inc. (RLMD) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Pharmaceuticals. Price $4.43, market value $473 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Relmada Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 92132.5×**. Each dollar of revenue is priced at 92132.5×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 0.4×**. The shares trade below book value, which can signal a bargain or a balance sheet the market doubts.

## Profitability
- **Gross margin: 21.3%**. Relmada Therapeutics Inc. keeps 21.3% of revenue after the direct cost of what it sells, a thin margin typical of retail, distribution and commodity businesses.
- **Operating margin: -877.7%**. Operating margin is negative: the business loses money before interest and tax.
- **Return on equity: -66.3%**. Return on equity is negative because earnings are negative.
- **Return on assets: -0.0%**. Each dollar of assets produces -0.0% of profit.

## Growth
- **EPS growth (1 yr): 45.3%**. Earnings per share rose 45.3%.

## Financial health
- **Current ratio: 14.62** (quick 14.62). Current assets cover the next year's liabilities 14.62 times.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Relmada Therapeutics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (5 analysts). 5 analysts cover Relmada Therapeutics Inc.; the consensus is strong_buy, with an average price target of $12.40 (+180% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 223.4%** (YTD -8.3%, 3-mo -25.5%). The shares are up 223.4% over twelve months including dividends.
- **From 52-week high: -44.6%** (207.6% above the low). Trading 45% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 37**. An RSI of 37 is neutral.
- **Beta (1 yr): 1.40** (volatility 105%). Beta of 1.40 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=RLMD · Page: https://foliofundamentals.com/stocks/rlmd

Not investment advice.